TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28864749
Drug: CYP3A5 genotype
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP3A5 genotype plus Wuzhi tablet co-administration guided dosing
Study: 28864749
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing of tacrolimus (control group)
Study: 16322487
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dextroamphetamine (AMPH) with physiotherapy
Study: 16322487
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dextroamphetamine (AMPH) with physiotherapy in moderate hemiparesis subgroup
Study: 10539775
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of L-[1-(13)C]oxoproline and L-[3, 3-(2)H]cysteine
Study: 10539775
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of L-[(15)N]oxoproline and L-[3,3-(2)H]cysteine
Study: 8758790
Drug: Intraperitoneal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal administration of DDP (100mg/m2)
Study: 8758790
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of DDP (100mg/m2)
Study: 1913123
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue plasminogen activator (IV rt-PA)
Study: 6749773
Drug: Atropine 0.13
Normalized name: ATROPINE 0.13/PHENOBARBITAL 15MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.13 mg
Study: 6363488
Drug: Atropine 0.26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.26 mg
Study: 6749773
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of atropine (exact dosage not specified)
Study: 31440032
Drug: IDP‐73152 mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP‐73152 mesylate 40-320 mg
Study: 31440032
Drug: IDP‐73152 mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP‐73152 mesylate 640 mg (fed state)
Study: 26053170
Drug: SPD left‐side
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPD left‐side down (SPD‐L)
Study: 23277897
Drug: High-dose influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose influenza vaccine (60 mcg/strain)
Study: 23277897
Drug: Standard-dose influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose influenza vaccine (15 mcg/strain)
Study: 19879995
Drug: LEISH-F1+MPL-SE vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEISH-F1+MPL-SE vaccine (10 microg recombinant Leishmania polyprotein LEISH-F1 antigen + 25 microg MPL-SE adjuvant)
Study: 20688040
Drug: LEISH-F1+MPL-SE vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEISH-F1+MPL-SE vaccine
Study: 16930788
Drug: Single subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous palmar injection blocks
Study: 16930788
Drug: Palmar techniques
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmar techniques (including single subcutaneous palmar block and transthecal block)
Study: 9331018
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (combined treatment)
Study: 3120484
Drug: Intramuscular nicomorphine
Normalized name: nicomorphine
DrugBank: Nicomorphine (DB13454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular nicomorphine post-operatively
Study: 30206090
Drug: Mexiletine hydrochloride
Normalized name: Mexiletine Hydrochloride
DrugBank: Mexiletine (DB00379)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mexiletine hydrochloride (300 mg/day) administered orally three times a day for 4 weeks (period 1)
Study: 30206090
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally three times a day for 4 weeks (period 1)
Study: 24347765
Drug: melatonin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: melatonin (6 mg)
Study: 24347765
Drug: gabapentin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: gabapentin (600 mg)
Study: 18237297
Drug: Pre-injection anxiety
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-injection anxiety levels
Study: 11106143
Drug: Melatonin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (2 mg in a controlled-release formulation)
Study: 9064946
Drug: Dobutamine (maximal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine (maximal dose: 9 micrograms/kg/min; n = 10)
Study: 1370510
Drug: Immunotherapy (IT)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (IT) with alum-precipitated aqueous ragweed extracts
Study: 6383654
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (average dose 845,000 U iv, administered at 2.8 ± 1.0 hr after onset of pain)
Study: 6383654
Drug: Intracoronary streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary streptokinase (average dose 212,000 U ic, administered at 4.3 ± 1.4 hr after onset of pain)
Study: 6383654
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control group (not specified dosage or timing)
Study: 30261892
Drug: Soluble keratin
Normalized name: gold keratinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble keratin (KER) 0.8 g/kg bodyweight/day
Study: 26817502
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (30 mg Zn/d)
Study: 26817502
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 mg Zn/d)
Study: 24472253
Drug: 8 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks of preschool-based social communication treatment in addition to standard preschool program
Study: 23257132
Drug: Qianggu Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qianggu Capsule and two disease-modifying antirheumatic drugs
Study: 23257132
Drug: Two common-used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two common-used antirheumatic drugs
Study: 20698724
Drug: 1.3 g
Normalized name: glycerin 1.3 g RECTAL SUPPOSITORY
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.3 g tranexamic acid
Study: 20698724
Drug: 3.9 g
Normalized name: aspirin 3.9 GM Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.9 g tranexamic acid
Study: 20698724
Drug: 0.4 g
Normalized name: psyllium 0.4 GM Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g moxifloxacin (positive control)
Study: 15458612
Drug: Hypericum extract
Normalized name: Hypericum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum extract (HE) 900 mg/d
Study: 7594327
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg and clarithromycin 400 mg (group 1, n = 22)
Study: 7594327
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg and clarithromycin 800 mg (group 2, n = 12)
Study: 7594327
Drug: Lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60 mg and clarithromycin 800 mg (group 3, n = 29)
Study: 7594327
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg (n = 23)
Study: 7594327
Drug: Lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60 mg (n = 13)
Study: 7594327
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg (n = 15)
Study: 160348
Drug: Sulindac 100
Normalized name: sulindac 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac 100 mg twice daily
Study: 22480093
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg thrice daily
Study: 160348
Drug: Soluble aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble aspirin 600 mg thrice daily
Study: 27785095
Drug: Nattokinase (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nattokinase (100 mg/d)
Study: 11167594
Drug: Adjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant systemic therapy (including chemotherapy)
Study: 11167594
Drug: More than
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More than one course of chemotherapy
Study: 9728898
Drug: Verapamil (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (240 mg/day for 2 days)
Study: 1424416
Drug: Fluvoxamine 50
Normalized name: fluvoxamine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 50 mg
Study: 277253
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hyperbaric oxygen and misonidazole
Study: 30095536
Drug: Opicinumab (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicinumab (100 mg/kg intravenous every 4 weeks for 6 infusions)
Study: 21487327
Drug: 7‐valent pneumococcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7‐valent pneumococcal conjugate vaccine + DTPa‐IPV‐Hib
Study: 19555810
Drug: Flavocoxid (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavocoxid (500 mg BID)
Study: 15037526
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg BID)
Study: 9824786
Drug: Rifampicin 300
Normalized name: Rifampicin 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 300 mg/day for 10 days
Study: 9824786
Drug: Rifabutin 300
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin 300 mg/day for 10 days
Study: 2509069
Drug: Netilmicin 300
Normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Netilmicin 300 mg once daily (group A)
Study: 2509069
Drug: Netilmicin 100
Normalized name: netilmicin 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netilmicin 100 mg three times daily (group B)
Study: 31898756
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) cheek fillers injection
Study: 28109247
Drug: Internet- and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet- and mobile-based intervention (IMI) for depression prevention, based on cognitive behavioral therapy (CBT) principles, comprising six weekly modules and two booster sessions.
Study: 9572900
Drug: Colon-Targeted Delivery
Normalized name: Sus scrofa colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colon-Targeted Delivery Capsule
Study: 7922092
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (prednisolone, cyclosporin A, azathioprine)
Study: 7922092
Drug: Low-dose cyclosporin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose cyclosporin, azathioprine, and prednisolone
Study: 7922092
Drug: High-dose cyclosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclosporin and prednisolone
Study: 7922092
Drug: High-dose cyclosporin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclosporin, nifedipine, and prednisolone
Study: 3136953
Drug: Heparin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin alone (27 patients)
Study: 3136953
Drug: Maintenance infusion
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance infusion of rt-PA at 0.8 mg/kg during 4 hours (25 patients)
Study: 31713266
Drug: 1064-nm Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1064-nm Nd:YAG laser treatment
Study: 30587761
Drug: 250 mg/day
Normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/day of elemental Mg for three months
Study: 24356481
Drug: golimumab 100
Normalized name: golimumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab 100 mg + placebo
Study: 23327125
Drug: Midazolam (MDZ)
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam (MDZ) 0.2 mg/kg
Study: 15941886
Drug: Plant sterols
Normalized name: Plant Sterols/Stanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterols (1.8 g/d)
Study: 10622655
Drug: Felodipine infusion
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine infusion during the hypothermic period of cardiopulmonary bypass
Study: 10622655
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no felodipine infusion)
Study: 8622115
Drug: Isepamicin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isepamicin (8 or 15 mg/kg once daily)
Study: 8622115
Drug: Isepamicin (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isepamicin (7.5 mg/kg twice daily)
Study: 28933613
Drug: Partnered ballroom
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partnered ballroom dancing, 1 hour, twice a week for 10 weeks, led by professional dance teachers.
Study: 18270675
Drug: S(+)-ketamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)-ketamine (0.25 mg/kg BW bolus followed by infusion of 0.06 mg/kg BW/h)
Study: 18270675
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (>3 mg/kg BW/h)
Study: 10549452
Drug: Foaming tablet
Normalized name: Rectal Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foaming tablet
Study: 8154255
Drug: Retrobulbar anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar anesthesia with 150 I.U. hyaluronidase (Kinetin) added to 4 mg lidocaine 2% with adrenalin
Study: 24882370
Drug: Spa treatment
Normalized name: Salicylic Acid 5 mg in 1 mL TOPICAL LOTION [ageLOC LumiSpa Treatment Cleanser Acne]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa treatment combined with consultation with dietician
Study: 19535425
Drug: Iron (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron (25 mg) and folic acid (100 microg) for 90 days
Study: 19535425
Drug: Iron (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron (25 mg) and folic acid (100 microg) with multivitamins and/or anthelminthics
Study: 19535425
Drug: Iron (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron (25 mg) and folic acid (100 microg) with adherence higher than the median
Study: 19535425
Drug: High-dose daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose daily iron+folic acid
Study: 17595891
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg rivaroxaban once, twice or three times daily, or 10, 20 or 30 mg rivaroxaban twice daily
Study: 9709470
Drug: Chlorambucil (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorambucil (0.15 mg/kg/day for months 2, 4, and 6) and steroids (1 g methyl‐prednisolone i.v. on three consecutive days, followed by oral prednisone 0.5 mg/kg/day for months 1, 3, and 5)
Study: 9709470
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide (1.5‐2.0 mg/kg/day for 1 year) and steroids in a comparable dose
Study: 1870651
Drug: Compulsory inpatient
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compulsory inpatient treatment
Study: 1870651
Drug: Choice of
Normalized name: HYDROGEN PEROXIDE 30 mg in 1 mL TOPICAL LIQUID [MediChoice of Hydrogen Peroxide 3 10 Volume]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choice of treatment options
Study: 6314140
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion at 0.1 microgram per kilogram per minute
Study: 6314140
Drug: Isoproterenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol infusion at 0.02 micrograms per kilogram per minute
Study: 6314140
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion at 0.05 micrograms per kilogram per minute after administration of ICI 118551 (2.5 or 5 mg)
Study: 6314140
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion after placebo
Study: 27726259
Drug: Programmed sports
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed sports therapy (PST) for 6 months
Study: 25231896
Drug: Mirogabalin 5
Normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mirogabalin 5 mg/day
Study: 25231896
Drug: Mirogabalin 10
Normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mirogabalin 10 mg/day
Study: 28371941
Drug: Mirogabalin 15
Normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mirogabalin 15 mg/day
Study: 28371941
Drug: Mirogabalin 20
Normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mirogabalin 20 mg/day
Study: 28371941
Drug: Mirogabalin 30
Normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mirogabalin 30 mg/day
Study: 21769661
Drug: Combined vertebroplasty
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vertebroplasty with antiresorptive agent
Study: 9795914
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg lamivudine once daily
Study: 29428872
Drug: Ramipril treatment
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril treatment
Study: 19206035
Drug: Four-week inpatient
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-week inpatient treatment
Study: 12207834
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g cis‐9,trans‐11-trans‐10,cis‐12 isomeric blend (50 : 50) CLA
Study: 12207834
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g cis‐9,trans‐11-trans‐10,cis‐12 isomeric blend (80 : 20) CLA
Study: 31932108
Drug: Pazopanib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 600 mg once daily and fosbretabulin 54 mg/m2 on days 1, 8, and 15 (phase 1b)
Study: 31932108
Drug: Pazopanib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 600 mg once daily and fosbretabulin 54 mg/m2 (experimental arm)
Study: 31932108
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg once daily (control arm)
Study: 28285280
Drug: Delayed cord
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed cord clamping (60 s) with ergometrine (500 µg)
Study: 28010726
Drug: Anti-TNF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF treatment
Study: 24307311
Drug: Chaiqin Chengqi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chaiqin Chengqi Decoction (CQCQD) administered by gastric perfusion (50 mL/2 h) and retention enema (200 mL/6 h) for 7 days
Study: 21876349
Drug: Bindarit (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bindarit (1,200 mg/day)
Study: 19236643
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg x kg(‐1) propofol
Study: 19236643
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg x kg(‐1) propofol
Study: 11129620
Drug: Midazolam-fentanyl (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam-fentanyl (group M) - intravenous midazolam 0.1 mg.kg‐1.h‐1 and fentanyl 25 micrograms.kg‐1 until sternotomy
Study: 11129620
Drug: Propofol-fentanyl (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-fentanyl (group P) - intravenous propofol 4 mg.kg‐1.h‐1 and fentanyl 25 micrograms.kg‐1 until sternotomy
Study: 9085210
Drug: Hexoprenaline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexoprenaline (10 micrograms administered intravenously)
Study: 8239010
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg diazepam
Study: 8239010
Drug: 0.03 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg/kg oral atropine
Study: 3010028
Drug: Atenolol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (beta 1-blocker, 50 mg once per day)
Study: 3010028
Drug: ICI 118,551
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118,551 (beta 2-blocker, 20 mg t.i.d.)
Study: 3010028
Drug: ICI 118,551
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118,551 (beta 2-blocker)
Study: 3010028
Drug: Atenolol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (beta 1-blocker)
Study: 28077539
Drug: Group R
Normalized name: Typhus group rickettsia Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group R (remifentanil 0.30 µg kg‐1 min‐1)
Study: 28077539
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (remifentanil 0.30 µg kg‐1 min‐1 and pre‐anaesthesia butorphanol 20 µg kg‐1)
Study: 28077539
Drug: Group BF
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group BF (remifentanil 0.30 µg kg‐1 min‐1 and pre‐anaesthesia butorphanol 10 µg kg‐1 combined with flurbiprofen axetil 0.5 mg kg‐1)
Study: 28077539
Drug: Group S
Normalized name: Blood group substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group S (sufentanil 0.30 µg kg‐1)
Study: 11823755
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg olanzapine with 500 mg probenecid
Study: 11823755
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg risperidone with 500 mg probenecid
Study: 11823755
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg olanzapine alone
Study: 11823755
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg risperidone alone
Study: 10027031
Drug: Propofol infusion,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol infusion, 30 mg.kg‐1.h‐1 (Group P; n = 12)
Study: 10027031
Drug: Ketamine bolus,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine bolus, 0.5 mg i.v. followed by propofol infusion, 30 mg.kg‐1.h‐1 (Group PK0.5; n = 12)